Skip to Content

Vimizim Approval History

FDA Approved: Yes (First approved February 14, 2014)
Brand name: Vimizim
Generic name: elosufase alfa
Dosage form: Injection
Company: BioMarin Pharmaceutical Inc.
Treatment for: Mucopolysaccharidosis Type IVA

Vimizim (elosufase alfa) is an enzyme replacement therapy for patients with Mucopolysaccharidosis Type IVA (Morquio A syndrome).

Development History and FDA Approval Process for Vimizim

DateArticle
Feb 16, 2014Approval FDA Approves Vimizim to Treat Mucopolysaccharidosis Type IVA
Nov 20, 2013FDA Advisory Committee Recommends Approval of Vimizim for Morquio A Syndrome

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide